Dietary Supplements' Regulation: Are We Doing Enough to Protect the Children? A Narrative Review

Jelena Jovičić-Bata1, Nataša Milošević1, Neda Gavarić1

  • 1Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia.

PubMed

Insights

Regulatory inconsistencies in the European Union and Serbia pose risks to pediatric dietary supplements (DS). Addressing these gaps is crucial for ensuring children

Area of Science:

  • Public Health
  • Regulatory Science
  • Pediatric Nutrition

Background:

  • High prevalence of pediatric dietary supplement (DS) use necessitates stringent regulation.
  • Current regulatory frameworks in the EU and Serbia exhibit inconsistencies, potentially compromising pediatric DS safety.

Purpose of the Study:

  • To critically evaluate regulatory and practical issues concerning the definition, labeling, advertising, and use of pediatric DS in the EU and Serbia.
  • To identify inconsistencies and gaps in legal and policy frameworks impacting pediatric DS safety.

Main Methods:

  • A comprehensive review of legal and policy frameworks in the EU and Serbia.
  • Analysis of peer-reviewed literature on pediatric DS definition, labeling, and advertising.
  • Assessment of marketing practices and their impact on consumer safety.

Main Results:

  • Identified five critical regulatory concerns: unclear product definition, lack of uniform composition standards, safety risks from ambiguous standards and age cut-offs, misuse of labels/unfair advertising, and limited healthcare provider involvement.
  • Highlighted the absence of age-appropriate reference values for pediatric DS.

Conclusions:

  • Regulating pediatric DS is complex due to population diversity.
  • Regulatory systems require adaptability to scientific advancements and market changes to prioritize children's health and safety.
  • Swift resolution of inconsistencies is essential for effective pediatric DS oversight.
Abstract

Related Concept Videos

Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...